Transferrin receptor targeting chimeras for membrane protein degradation

Dingpeng Zhang(Harvard University), Jhoely Duque-Jimenez(Dana-Farber Cancer Institute), Francesco Facchinetti(Harvard University), Garyk Brixi(Harvard University), Kaitlin Rhee(Harvard University), William W. Feng(Harvard University), Pasi A. Jänne(Harvard University), Xin Zhou(Harvard University)
Nature
September 25, 2024
10.1038/s41586-024-07947-3
Cited by 139Open Access
Full Text

Abstract

Related Papers

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al.|New England Journal of Medicine|2005|3.9k
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al.|Science Translational Medicine|2011|3.6k
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al.|Clinical Cancer Research|2013|2.5k
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al.|Cancer Discovery|2014|2.2k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al.|Nature Medicine|2015|1.5k